

**Identity:**

Title: Professor  
 Family Name(s): Kardys  
 First Name(s): Isabella  
 Age: 44

**Photo:****Application for the following position in the HFA Board or Nominating Committee:**

Ordinary Board member

**Place of work**

Institute/organisation:	Erasmus MC University Medical Center Rotterdam
Department:	Cardiology
Address:	Dr. Molewaterplein 40
Post code / Zip:	3015GD Rotterdam
Country:	The Netherlands

**General Curriculum Vitae (500 words max)****Personal statement**

As a full professor of translational cardiovascular epidemiology, I lead a research line focusing on innovative methodological approaches in clinical-epidemiological studies of acquired heart disease, including heart failure; particularly emphasizing serially measured blood biomarkers. My work bridges the gap between pre-clinical science and clinical practice, with significant contributions in heart failure such as 1) demonstrating divergent temporal patterns of circulating protein levels before adverse clinical events and their prognostic utility, and 2) identifying dynamic proteomic-based subphenotypes. I have secured over €5 million in grants as a principal investigator, leading several multicenter patient cohort studies, among which Bio-SHiFT (HFrEF) and ADAPT-HFpEF (enrollment ongoing). I collaborate with consortia such as Secur-e-Health (ITEA3), IMI BigData@Heart, HERMES; EURObservational Research Programme (EORP); and companies including Labcorp, SomaLogic, Olink.

**Education**

2007 PhD, Department of Epidemiology & Biostatistics, Erasmus MC Rotterdam  
 2004 MD, Medicine (and 2002 MSc, Medicine), Erasmus MC Rotterdam  
 2002 MSc, Clinical Epidemiology, Netherlands Institute for Health Sciences (NIHES), Rotterdam

**Positions/Employment**

2022- Full professor, dept. of Cardiology, Erasmus MC Rotterdam  
 2011- 2022 Assistant and associate professor, idem  
 2011 - 2012 Senior researcher, Netherlands Heart Institute (NHI), Utrecht  
 2010 - 2011 Postdoc researcher, dept. of Cardiology, Erasmus MC Rotterdam  
 2007 - 2010 Resident (Internal Medicine and Cardiology); Erasmus MC; Amphia Hospital, Breda; Maastad Hospital, Rotterdam  
 2006 Research fellow, Center for Cardiovascular Disease Prevention, Harvard Medical School, Boston, USA

**Supervision**

2010 – Supervised 20 PhD students as formal thesis supervisor (co-promotor or promotor), as well as 3 postdocs and >10 MSc students.

## Publications

H-index:	34
Sum of Times Cited:	10099
# International articles (any position):	229
# International articles (first position):	17
# International articles (last position):	54

### Top publications, last 5 years

1. Petersen TB, (...), **Kardys I.** HFREF subphenotypes based on 4210 repeatedly measured circulating proteins are driven by different biological mechanisms. EBioMedicine. 2023 Jul;93:104655.
2. de Bakker M, (...), **Kardys I.** Machine learning-based biomarker profile derived from 4210 serially measured proteins predicts clinical outcome of patients with heart failure. Eur Heart J Digit Health. 2023 Oct 4;4(6):444-454.
3. de Bakker M, (...), **Kardys I.** Sex-based differences in cardiovascular proteomic profiles and their associations with adverse outcomes in patients with chronic heart failure. Biol Sex Differ. 2023 May 17;14(1):29.
4. Shakoar A, Abou Kamar S, Malgie J, **Kardys I**, Schaap J, de Boer RA, van Mieghem NM, van der Boon RMA, Brugts JJ. The different risk of new-onset, chronic, worsening, and advanced heart failure: A systematic review and meta-regression analysis. Eur J Heart Fail. 2023 Oct 12.
5. Abou Kamar S, Aga YS, de Bakker M, van den Berg VJ, Strachinaru M, Bowen D, Frowijn R, Akkerhuis KM, Brugts JJ, Manintveld O, Umans V, Geleijnse M, de Boer RA, Boersma E, **Kardys I\***, van Dalen BM\* (\*equal contribution) Prognostic value of temporal patterns of left atrial reservoir strain in patients with heart failure with reduced ejection fraction. Clin Res Cardiol. 2023 Jun 13.
6. Baart SJ, (...), **Kardys I.** Relative conditional survival analysis provides additional insights into the prognosis of heart failure patients. Eur J Prev Cardiol. 2022 Mar 11;29(2):e72-e73.
7. Schuurman AS, (...), **Kardys I.** Personalized screening intervals for measurement of N-terminal pro-B-type natriuretic peptide improve efficiency of prognostication in patients with chronic heart failure. Eur J Prev Cardiol. 2021 Aug 9;28(9):e11-e14.

## Describe previous experience within the HFA, ESC and/or your National Cardiac/ HF Society

### Professional Memberships

2024 -	ESC Heart Failure Association Gold member
2023 - 2024	ESC Heart Failure Association Silver member
2023 -	ESC Working Group on e-Cardiology
2017 -	ESC Working Group on Atherosclerosis & Vascular Biology
2016 - 2021	Dutch Cardiovascular Alliance (DCVA), Board member of Young@Heart (talent pillar)
2016 -	ESC Fellow
2010 -	ESC, member
2010 -	Netherlands Society of Cardiology (NVVC), member
2010 -	Epidemiologist B, Society for Epidemiology (VvE)

**ESC Editorial Board Positions**

2024 - Deputy Editor, European Heart Journal – Digital Health  
2020- Editorial board European Heart Journal – Digital Health  
2012 - 2020 Editorial board EuroIntervention

**Why are you motivated to join the HFA Board or Nominating Committee?**

Over the past decade, my primary focus in research has been on heart failure. I integrate elements from molecular biology (blood biomarkers), statistics, bio-informatics and modern epidemiology, to gain insights into heart failure pathophysiology and to develop personalized prognostication tools for clinical use. For example, within the BigData@Heart IMI Consortium I have employed machine learning to derive prognostic models and subphenotypes of heart failure, based on comprehensive and longitudinally measured proteomics data. My work in machine learning and associated clinical prognostic tools has also sparked my interest in e-Cardiology, leading me to take on the role of Deputy Editor of EHJ–Digital Health. Given my background and the recent developments in heart failure care, which highlight the importance of personalized and remote health services, I believe I can offer valuable complementary expertise to the HFA Board. I would be honoured to apply my background to support the Board's objectives and thus contribute to the field of heart failure at this level.

**How will you combine your HFA position with your daily clinical/research workload?**

In my current position, my main responsibilities involve scientific research and teaching, along with all associated tasks. Therefore, serving as a member of the HFA board would align perfectly with my assigned duties. Given that a significant portion of my responsibilities allows for flexibility in terms of location and timing, this will afford me ample space and flexibility to dedicate the required time to this role.